Enrolled patients had a baseline or recent liver biopsy showing clinically significant MASLD (metabolic dysfunction-associated steatotic liver disease), defined as MASH with fibrosis stage 2 or 3 and a non-alcoholic fatty liver disease (NAFLD) Activity Score (NAS) 4 with a score of 1 or more in steatosis, lobular inflammation, and hepatocyte ballooning
Please note that if you call us at the telephone number displayed on our website, we will only know to a certain extent how you found us
Randomization and blinding The study was conducted between October and December 2012
For weight loss : Coverage is limited to a shrinking number of states, and requirements are strict
Anbarkeh FR, Baradaran R, Ghandy N, Jalali M, Nikravesh MR, Soukhtanloo M
ACT 1: What Is Foundayo, and Why Is It Different